Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Advanced Remedies Private Limited, is an unlisted private company incorporated on 01 May, 1997. It is classified as a private limited company and is located in , Maharashtra. It's authorized share capital is INR 4.00 cr and the total paid-up capital is INR 3.01 cr.
The current status of Advanced Remedies Private Limited is - Converted to LLP.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
9.29%
7.69%
-68.97%
2.15%
6.23%
5.07%
5.57
-0.31
-8.37
-8.01
-0.76
0.01
No Reports Available
Tofler currently has no financial reports
for this company due to a lack of available
information. This may be because the company
is dormant or closed (see company status)
or because it was formed only recently
(check the incorporation date) and financial data
is not yet available.
You can view basic information by scrolling through the page.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(1)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Raman Parameswaran Athipotta | 00025481 | 12 years |
| Director | Nitin Janardan Desai | 00028060 | 23 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| OKASA PRIVATE LIMITED |
Amalgamated
|
5.3 Cr | 1 | Maharashtra |
| E-MAN CONSULTANTS PRIVATE LIMITED |
Amalgamated
|
62.0 L | 1 | Maharashtra |
| CIPLA NATURAL SCIENCES PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Maharashtra |
| ORION LIFE SCIENCES PRIVATE LIMITED |
Converted to LLP and Dissolved
|
1.0 L | 1 | Maharashtra |
| CIPLA LIFE SCIENCES PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Maharashtra |
| MEDULE PHARMA PRIVATE LIMITED |
Converted to LLP
|
42.0 L | 1 | Maharashtra |
| DNA PHARMA PRIVATE LIMITED |
Converted to LLP and Dissolved
|
1.0 L | 1 | Maharashtra |
| MEDICREAMS INDIA PRIVATE LIMITED |
Converted to LLP and Dissolved
|
1.0 L | 1 | Maharashtra |
| DRUG DELIVERY SYSTEMS (INDIA) PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Maharashtra |
| METRO REMEDIES PRIVATE LIMITED |
Converted to LLP and Dissolved
|
1.0 L | 1 | Maharashtra |
| METRO ADVISORS PRIVATE LIMITED |
Converted to LLP and Dissolved
|
1.0 L | 1 | Maharashtra |
| MN RAJKUMAR GARMENTS PVT LTD |
Converted to LLP and Dissolved
|
1.0 L | 1 | Maharashtra |
| SHREE RIDDHI CHEMICALS PVT LTD |
Converted to LLP and Dissolved
|
1.0 L | 1 | Maharashtra |
| ALPS REMEDIES PRIVATE LIMITED |
Active
|
20.2 L | 1 | Maharashtra |
| IRIS PROPERTIES PRIVATE LIMITED |
Amalgamated
|
60.0 L | 1 | Maharashtra |
| OMNICARE SPECIALITIES PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Maharashtra |
| NEPTUNE REMEDIES PRIVATE LIMITED |
Amalgamated
|
77.0 L | 1 | Maharashtra |
| DREAMZ IMPEX PRIVATE LIMITED |
Converted to LLP and Dissolved
|
1.0 L | 1 | Maharashtra |
| HAMSONS LABORATORIES PRIVATE LIMITED |
Converted to LLP and Dissolved
|
40.0 L | 1 | Maharashtra |
| FLORAL FANTASY PRIVATE LIMITED |
Converted to LLP and Dissolved
|
1.0 L | 1 | Maharashtra |
| CENTAUR EXPORTS PRIVATE LIMITED |
Amalgamated
|
66.8 L | 1 | Maharashtra |
| LABH CONSULTANTS PRIVATE LIMITED |
Converted to LLP and Dissolved
|
2.5 Cr | 1 | Maharashtra |
| LABH CONSULTANTS LLP |
Active
|
2.5 Cr | 1 | Maharashtra |
| OKASA PHARMA PRIVATE LIMITED |
Active
|
22.0 L | 1 | Maharashtra |
| INHALED TECHNOLOGIES PRIVATE LIMITED |
Converted to LLP
|
2.5 Cr | 1 | Maharashtra |
| ONCOCARE INDIA PRIVATE LIMITED |
Converted to LLP
|
2.4 Cr | 1 | Maharashtra |
| PHARMASOLVE SPECIALITIES INDIA PRIVATE LIMITED |
Converted to LLP
|
1.0 Cr | 1 | Maharashtra |
| G M PARTITIONS PRIVATE LIMITED |
Amalgamated
|
100.0 | 1 | Maharashtra |
| MEDIMORE PHARMA PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Maharashtra |
The incorporation date of ADVANCED REMEDIES PRIVATE LIMITED is 01 May, 1997
The authorized share capital of ADVANCED REMEDIES PRIVATE LIMITED is INR ₹ 4.0 Cr.
The paid-up capital of ADVANCED REMEDIES PRIVATE LIMITED is INR ₹ 3.0 Cr.
The registered address of ADVANCED REMEDIES PRIVATE LIMITED is 12 GUNBOW STREETFORT MUMBAI Maharashtra - 400001
The CIN number of ADVANCED REMEDIES PRIVATE LIMITED is U73100MH1997PTC107712.
Expand
Delete
Collapse
See
details
